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Defined key terms: 5-10 
Mycobacterium tuberculosis: Causative bacterial agent of tuberculosis, 
responsible for 1.8 million deaths per year, with an estimated 2 billion people 
infected worldwide. 
Isoniazid: Front line anti-tuberculosis drug targeting fatty acid synthesis (FASII) 
and affecting the mycobacterial cell wall; responsible for the majority of 
mycobacterial killing within the first 2 days of treatment with standard regimen. 
Persistence: Bacilli capable of causing active disease that survive prolonged 
chemotherapy, resulting in lengthy and expensive treatment for tuberculosis. 
Phenotypic drug tolerance: Mechanisms by which genetically susceptible 
bacilli are refractory to killing with anti-microbial agents. Tolerance may be 
dependent on pre-existing sub-populations of physiologically distinct bacilli, or 
may be initiated by changes in the microenvironment or drug exposure. 
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Transcriptional profiling by microarray: Exploring the global responses of 
bacilli to the surrounding microenvironment by simultaneously quantifying 
mRNA abundance for all defined M.tuberculosis genes. 
Wayne model: An in vitro model where primarily oxygen is limited to mimic 
M.tuberculosis non-replicating persistence. 
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Abstract 
Background: Understanding how growth state influences M.tuberculosis 
responses to antibiotic exposure provides a window into drug action during 
patient chemotherapy. Here, we describe the transcriptional programs mediated 
by isoniazid (INH) during the transition from log phase to non-replicating bacilli, 
from INH-sensitive to INH-tolerant bacilli respectively, using the Wayne model. 
Results and Conclusions: INH treatment did not elicit a transcriptional 
response from non-replicating bacteria under microaerophilic conditions 
(NRP2), unlike the induction of a robust and well-characterized INH signature in 
log phase bacilli. The differential regulation (between drug-free NRP2 and log 
phase bacilli) of genes directly implicated in INH resistance could not account 
for the abrogation of INH killing in non-growing bacilli. Thus, factors affecting the 
requirement for mycolic acids and the redox status of bacilli are likely 
responsible for the reduction in INH efficacy. We speculate on additional 
mechanisms revealed by transcriptome analysis that might account for INH 
tolerance. 
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Introduction 
While effective at resolving active Mycobacterium tuberculosis disease, current 
TB chemotherapy requires multiple drugs to be taken over six months to clear 
infection of genotypically drug-sensitive bacilli. This long treatment period exerts 
huge demands on healthcare infrastructure and finances, and risks the 
emergence of drug resistance through poor patient compliance. The search for 
a more effective shortened drug regimen is complicated by the presence of 
persistent organisms, likely phenotypically drug tolerant bacilli, that need 
prolonged drug treatment to clear (1) (2). 
 
Phenotypic tolerance, unlike genetically defined resistance, is a transient 
bacterial state in which many antibiotics are ineffective. Tolerance is likely 
dependent upon pre-existing sub-populations of genetically susceptible bacteria 
in a slow/non-multiplying state that are refractory to drug action (3). This small 
fraction of phenotypically distinct bacteria enable bacterial populations to 
survive dramatic changes in the environment (4). In addition to stochastic 
mechanisms that create sub-populations of non-growing cells in a 
phenotypically heterogeneous bacterial community, recent evidence suggests 
that tolerant bacterial sub-populations may be generated after antibiotic stress 
(5). In TB clinical settings, phenotypically tolerant bacilli are likely to be 
responsible for the persistence of M.tuberculosis bacilli through the drug 
treatment period (6). We speculate that phenotypically tolerant bacilli in patients 
may exist as a result of: i) stochastic processes; ii) through exposure of bacilli to 
multiple microenvironments imposing individual constraints on growth that may 
be temporally and spatially separated; and iii) through prolonged antibiotic 
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stress. There is sparse information defining sub-populations of M.tuberculosis, 
but both clinical data and the demonstration of sub-populations from in vitro 
culture and animal models (7) (8) indicate that sub-populations exist. Further in 
vivo evidence is provided by quantitative variations in lipid inclusion body 
staining of human sputum-derived bacilli (9), and the observation that bacilli in 
different locations of human lung tissues display unique gene expression 
patterns (10). Furthermore, murine models of chronic infection show increased 
tolerance to isoniazid, suggesting slow growth rates are associated with 
reduced drug efficacy (11). 
 
Isoniazid (INH) is a front-line drug in TB treatment and prophylaxis. Bactericidal 
activity during the first 2 days of TB treatment is almost entirely due to INH 
eliminating around 90% of bacilli (12). However, minimal killing is observed after 
exposure of non-replicating M.tuberculosis bacilli to INH in vitro (13), so it is 
unlikely that INH contributes to the clearance of persistent bacilli in patients 
during the extended treatment phase. INH is a pro-drug that enters the cell by 
passive diffusion where it is converted by a katG-encoding catalase-peroxidase 
to an active INH-NAD adduct; reviewed in (14). The primary target of INH-NAD is 
InhA, an enoyl-ACP reductase, part of the FASII cycle, that is required for 
mycolic acid synthesis and maintenance of the mycobacterial cell wall structure 
(15) (16). The INH-NAD(P) adduct(s) are likely to inhibit multiple secondary 
targets, such as the NADPH-dependent dihydrofolate reductase, that may also 
contribute to INH-mediated killing (17). Resistance to INH is most frequently 
determined by mutations in katG, inactivating the catalase-peroxidase required 
for INH pro-drug conversion. Mutations in the promoter of inhA, resulting in the 
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over-expression of the target (inhA) or affecting the InhA active site also confer 
resistance (18). Mutations in a number of other genes have been identified in 
INH-resistant M.tuberculosis strains (19). However, approximately 22-29% of 
INH-resistant strains do not possess mutations in genes known to affect INH-
resistance (20) (21), indicating that there may be unexplored mechanisms that 
influence INH efficacy in M.tuberculosis. 
 
Transcriptional profiling by microarray analysis has been used extensively to 
define the M.tuberculosis genome-wide responses to antibiotic exposure 
(classifying drug action and identifying possible resistance mechanisms) (22) (23) 
(24) and fluctuations in environmental factors such as limited oxygen (25) (26) (27) or 
nutrient starvation (28) (29); reviewed in (30). In one such model of mycobacterial 
persistence developed by Wayne and colleagues (31), oxygen levels are 
gradually reduced by stirring liquid cultures in sealed tubes. Under these 
conditions, bacilli enter a physiological state known as non-replicating 
persistence (NRP), which is characterized by two distinct stages. The first, 
NRP1, occurs in microaerophilic conditions when the concentration of oxygen in 
the medium descends to 1%. During this phase, bacilli shut down DNA 
synthesis and cell division, restrict biosynthetic activity, and use alternative 
energy sources to stabilize and protect essential cell components. The second 
NRP2 stage, where general metabolism is reduced further and replication 
ceases, occurs in anaerobic conditions when the dissolved oxygen 
concentration drops below 0.06% (13). Non-replicating bacteria may become 
tolerant to antibiotic exposure (32) (33); bacilli in NRP2 exhibit some definite but 
reduced killing with rifampicin and are highly tolerant to isoniazid and 
 8 
ciprofloxacin (31). Furthermore the absence of an isoniazid-inducible 
transcriptional signature has been used to characterize in vitro and in vivo M.tb 
dormant states (34). 
 
In an attempt to understand why non-replicating bacilli are refractory to killing by 
INH, and thus to identify putative INH-tolerance mechanisms mediated by 
changing transcript abundance, we defined the transcriptional responses to INH 
exposure in log phase and Wayne model NRP2 bacilli. Having contrasted the 
changing pattern of gene expression through the transition from log phase to 
NRP2 with the INH-induced transcriptome signature, we also discuss INH 
tolerance in non-growing populations and consider mechanisms that may 
influence drug tolerance. 
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Experimental 
Aerobic log-phase and Wayne model cultures 
Seed cultures of Mycobacterium tuberculosis H37Rv were incubated in 10 ml 
Dubos liquid medium (Difco) supplemented with Dubos medium albumin, with 
shaking at 37ºC for 6 days to an optical density 580 nm of 0.4. Both aerobic and 
non-replicating persistence (NRP) cultures were set up in glass tubes (125 by 
20 mm) with screw-top lids containing 1.5 mm magnetic stir bars, and stirred at 
120 rpm as characterized by Wayne (35). Log phase bacilli were incubated for 3 
days in 10 ml Dubos medium in tubes with loosened caps. The Wayne model 
cultures were incubated for 6 days (NRP1) or 21 days (NRP2) in 17 ml Dubos 
medium in tubes with sealed lids (with a resulting head-space ratio of 0.5). 
Growth was monitored by measuring optical density every 24h. RNA was 
isolated from aerobic log-phase and Wayne model cultures on two independent 
occasions. 
 
Isoniazid treatment 
Cultures were treated with 0.2 g/ml isoniazid (INH) final concentration (from 
100 g/ml stock solution, Sigma) at days 6 and 21 in the Wayne model (for 
NRP1 and NRP2 respectively), and at day 3 in log phase aerobic cultures. An 
equivalent volume of sterile water was added to drug-free carrier control 
samples. Mycobacterial RNA was extracted after exposure to INH for 4h. Prior 
to addition, syringes containing INH (or sterile water) were pre-incubated in an 
anaerobic cabinet overnight, to eliminate oxygen from the solutions and prevent 
the reintroduction of dissolved oxygen to the NRP cultures. 
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Mycobacterial RNA isolation 
RNA was extracted using the GTC/TRIzol method (36) (37); at each timepoint the 
culture volume (8 tubes per condition) was added to 4 volumes of 5 M 
guanidine thiocyanate solution, and the bacteria harvested by centrifugation. 
The bacilli were lysed in TRIzol using a reciprocal shaker, and the nucleic acid 
extracted with chloroform, before isopropanol precipitation. The RNA samples 
were purified and DNase I treated on RNeasy columns (Qiagen). Total RNA 
concentration was determined by spectrophotometry (NanoDrop ND-1000 3.1, 
NanoDrop Technologies), and size distribution assessed using an Agilent 2100 
Bioanalyser (Agilent Technologies). 
 
Microarray hybridization 
Whole-genome microarrays generated by the Bacterial Microarray Group at St. 
George’s (ArrayExpress accession number A-BUGS-23 (101)) were hybridized as 
described previously (38) (37). Briefly, 5 g cDNA derived from each RNA sample 
and 2 g M.tb H37Rv genomic DNA were labeled with Cy5-dCTP and Cy3-
dCTP respectively. RNA extracted from two biological replicates were 
hybridized in triplicate, resulting in 6 hybridizations per condition. Microarrays 
were scanned at 532 nm and 635 nm corresponding to Cy3 and Cy5 excitation 
maxima using the Affymetrix 428TM Array Scanner (MWG). Comparative spot 
intensities from the images were calculated using Imagene 5.5 (BioDiscovery), 
and the data imported into GeneSpring GX 7.3.1 (Agilent Technologies) for 
analysis. The data were normalized to the 50th percentile of all genes detected 
to be present, and filtered to include genes flagged to be present in 80% of the 
arrays. 
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Transcriptional profiling analysis 
Genes significantly differentially expressed between growth states or after 
isoniazid treatment were identified using a t-test with Benjamini and Hochberg 
multiple testing correction (p<0.05), and a minimum fold change of 1.5. Genes 
were hierarchically clustered using Cluster and the results displayed using 
Treeview (39). The hypergeometric distribution was used to determine if 
previously identified gene expression signatures, or genomic functional 
categories were significantly enriched in each comparison (40). Significantly 
differentially expressed genes are detailed further in Supplementary Tables 1 
and 2. Fully annotated microarray data from this study have been deposited in 
BG@Sbase (accession number: E-BUGS-104 (102)) and ArrayExpress 
(accession number: E-BUGS-104). 
 
Quantitative RT-PCR 
Primers and probes for cydA, efpA, icl, inhA, iniA, kasA, katG, narX, ndh and 
tgs1 were designed using the Primer Express 1.0 software (Applied 
Biosystems), and are detailed further in Supplementary Table 3. All probes 
were labeled with FAM (5-carboxyfluoroscein) at the 5’, and TAMRA (N,N,M’,N’-
tetramethyl-6-carboxyrhodamine) at the 3’. An internal control, sigA (labeled 
with VIC), was used to normalize mRNA levels. Mycobacterial RNA (5 g) was 
reverse transcribed in a total volume of 25 l using random primers (Invitrogen) 
according to the manufacturer’s instructions. 1 l of template cDNA was used 
for qRT-PCR with AmpliTaq Gold polymerase, alongside no template and no 
RT negative controls. qRT-PCR were performed using an ABI PRISM 7700 
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Sequence detector system (Applied Biosystems), amplification conditions 95ºC 
for 10 min followed by 50 cycles at 95ºC for 15s and 60ºC for 60s. Each 
reaction was performed in triplicate. The ΔΔCt method (41) was used to 
determine changes in relative gene expression. 
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Results and Discussion 
Gene expression programs illustrate the transition from log phase to non-
replicating persistence 
To examine the relationship between growth rate and phenotypic drug tolerance 
we used genome-wide microarray RNA profiling and qRT-PCR to map the 
transcriptional status of M.tuberculosis with and without exposure to isoniazid 
(INH) in log phase and in the Wayne model of non-replicating persistence 
(NRP). We hypothesize that transcriptome patterns may reveal mechanisms 
that explain INH tolerance, such as changes in expression levels for genes 
involved in drug efflux, alteration in target levels (inhA) or reduced katG 
expression (activation of drug). We first compared drug-free NRP bacilli to log 
phase bacilli (drug-free NRP2 vs. drug-free log phase) to describe the changes 
in gene expression that occur as oxygen and nutrients become limiting, as 
defined by Wayne and Hayes (31). 
 
As mycobacterial growth rate slows and then plateaus, 944 genes were 
significantly differentially expressed in NRP1 (323 induced, 621 repressed) and 
1451 genes differentially regulated in NRP2 (649 induced, 802 repressed) 
compared to aerobic log phase growth (Supplementary Table 1). As expected, 
there were highly significant overlaps in gene expression patterns with previous 
studies characterizing the transcriptional response of bacilli to stationary phase 
growth (26), oxygen limitation (25), nutrient starvation (28) and the Wayne model 
itself (42), with hypergeometric p-values for enrichment of NRP2-induced genes 
of 7.17x10-38, 3.44x10-18, 4.23x10-16 and 9.36x10-31 respectively. Genes with 
functional classifications (43) such as aerobic respiration, ribosomal protein 
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synthesis and ATP-proton motive force were repressed in NRP2 compared to 
aerobic axenic growth (hypergeometric p-values 5.14x10-8, 8.52x10-6 and 
4.34x10-5 respectively). Conversely, the dosR (44) (hypoxia and NO responsive 
dormancy regulon), mprA (45) (2-component response regulator) and kstR (46) 
(cholesterol metabolism) regulons were significantly induced in NRP2 compared 
to log phase growth (hypergeometric p-values 5.85x10-28, 6.10x10-5 and 
1.20x10-4 respectively); as were the alternative sigma factors sigB, sigE, sigF, 
sigG and the regulator of the stringent response, relA. The transition from 
rapidly multiplying to non-replicating bacilli in this Wayne model of dormancy 
mirrors previously identified transcriptional changes reflecting a change in 
respiratory state from aerobic to anaerobic as oxygen becomes limiting, a 
switch to lipid-based carbon sources as nutrients become scarce, and a 
modification of cell wall composition and a slowing of metabolism as growth 
terminates (27) (47). 
 
Non-replicating bacilli to do not mount a transcriptional response to 
isoniazid 
We then asked whether the transcriptional responses to INH would differ 
between these two physiologically distinct populations of bacilli. The hypothesis 
being that drug-induced responses reveal genes involved in potential resistance 
mechanisms or compensatory responses that reduce the effect of the drug and 
hence may underpin tolerance. We defined genes differentially expressed after 
4 h exposure to 0.2 g/ml isoniazid in log phase and NRP2 bacilli (in INH-
treated log phase vs. drug-free log phase, and INH-treated NRP2 vs. drug-free 
NRP2 comparisons). 
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In rapidly multiplying log phase bacilli, 100 genes were significantly differentially 
regulated after 4h INH treatment; with 71 genes induced and 29 genes 
repressed relative to drug-free log phase bacilli (Supplementary Table 2). There 
was a high degree of correlation between INH-responsive genes identified in 
this investigation and previous studies examining INH-mediated transcriptional 
programs; hypergeometric p-values (48) 2.15x10-24; (22) 5.79x10-16; (23) 3.54x10-12; 
and (49) 5.20x10-10. Genes indicative of cell wall inhibitors such as accA3, 
accD4, ahpC, ahpD, efpA, fadD32, fbpC, htdX, iniA, iniB, lprJ, pks16 and 
Rv3717 were significantly induced (23). Contrastingly, no genes were 
significantly differentially expressed after INH treatment of NRP2 bacilli relative 
to drug-free NRP2 bacilli. To ensure that the absence of differentially regulated 
genes after INH treatment in NRP2 bacilli was not an artifact of significance 
testing, we plotted the expression pattern of log phase INH-responsive genes in 
both log phase and NRP conditions (Figure 1a/b). Figure 1a shows a heat map 
of 6 replicates of all genes significantly up-regulated by INH in log phase bacilli 
and the gradual diminution of transcriptional response as transition proceeds 
through NRP1 towards NRP2. This confirmed that genes comprising the INH 
transcriptional signature of log phase bacilli were not differentially regulated 
after INH treatment in NRP2 bacilli. These observations were verified by 
quantitative RT-PCR using a panel of genes selected to be indicative of 
mycobacterial growth state and implicated in isoniazid resistance (Figure 2). 
Thus, increased tolerance of NRP2 bacilli to isoniazid seems not to be 
dependent on the initiation of a transcriptional program after exposure to INH 
that renders the drug ineffective. 
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The absence of a transcriptional response to isoniazid indicates no activity of 
the drug in NRP2 bacilli. This could be explained in several ways: i) INH has not 
entered the cell due to alterations in cell wall structure, or has been exported 
rapidly; ii) INH is not converted to the toxic product by KatG, or there is reduced 
availability of NAD to form the INH-NAD adduct; or iii) the enzyme target(s) of 
INH-NAD outnumber the toxic adducts generated, or the inhibition of pathways 
affected by INH are no longer functionally significant for bacilli in NRP2. We 
have utilized the gene expression signatures of NRP2 and INH as a framework 
to explore these hypotheses further. 
 
Differential regulation of genes identified to harbor mutations in INH-
resistant M.tuberculosis strains do not explain INH tolerance in NRP2 
Following the hypothesis that differences in transcript abundance between log 
phase and NRP2 bacilli might influence INH tolerance; we asked whether the 
differential regulation of genes associated with INH resistance might explain 
INH tolerance in NRP2 bacilli. On the assumption that differential expression of 
these genes (drug-free NRP2 vs. drug-free log phase) may relate to changes in 
protein (or drug) activity resulting in tolerance, even though these genes may 
not be directly involved in the mechanism of drug action. We therefore 
compared the expression profiles of 18 genes with mutations in INH drug-
resistant strains, collated on the Tuberculosis Drug Resistance Mutation 
Database (19), and present in the filtered microarray dataset used in this study 
(Figure 3). 
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Mutations that result in the over-expression of inhA (increased target) lead to 
INH resistance by overwhelming the active INH-NAD adduct present in exposed 
bacilli (14), however both inhA and the upstream gene fabG1 were repressed in 
NRP2 relative to log phase bacilli. An alternative mechanism of drug resistance 
might be caused by the increased activity of NAT (arylamine N-
acetyltransferase), which inactivates INH by acetylation leading to resistance. 
However the induction of nat was not observed in NRP2 compared to log phase 
bacilli. The catalase-peroxidase activity encoded by katG is required for the 
formation of the INH-NAD adduct; mutations in this gene result in INH 
resistance. Therefore, a down-regulation of katG could be hypothesized to 
increase INH tolerance. However, katG expression was induced in NRP2 
relative to log phase bacilli, which might be predicted to increase rather than 
decrease the susceptibility of NRP2 bacilli to killing by INH. Conversely, the 
activity of this catalase-peroxidase is reduced at low oxygen levels (50), which 
might result in the formation of less INH-NAD adduct and thus INH tolerance. 
Notably, this reduction of KatG activity in hypoxic conditions might also be 
predicted to result, through compensatory feedback mechanisms, in the 
induction of katG gene expression in NRP2 compared to log phase bacilli, 
which was observed. The repression of ndh, leading to a reduction in NDH-
attributed NADH dehydrogenase activity and an accumulation of NADH that 
acts as a competitive inhibitor with INH-NAD for INHA binding (51), increasing 
drug tolerance, was not evident. 
 
Genes identified as potentially influencing INH activity because they are highly 
up-regulated after INH treatment (52) (22) (such as fbpC, iniBAC, Rv1592c, 
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Rv1772 and efpA), were not induced in NRP2 compared to log phase growth as 
might be the case if these gene products contributed to INH tolerance in NRP2 
(Figure 3). Interestingly, fadE24, a probable acyl-CoA dehydrogenase likely 
involved in the -oxidation of fatty acids that is induced after INH exposure, was 
marginally induced in NRP2 relative to log phase bacilli. It has been previously 
proposed that the induction of genes involved in lipid degradation may be 
responsible for recycling fatty acids that accumulate after exposure to INH and 
the inhibition of the FASII cycle (22). The differential regulation of genes 
encoding efflux pumps may modify INH entry and exit kinetics affecting killing 
efficacy: efpA, mmr, Rv1819c, Rv2459 and Rv3728 have been demonstrated to 
be induced by INH in multi-drug resistant strains (53). However none of these 
genes were significantly induced in NRP2 relative to log phase growth. Of the 
genes assigned by Cole at al. (43) to the functional category III.A.6 efflux genes, 
3 were induced in NRP2 Rv1250 (a probable drug-transport integral membrane 
protein, member of the major facilitator superfamily), Rv1634 (a possible drug 
efflux protein, also member of the MFS family) and Rv2209 (a conserved 
integral membrane protein); 4 genes were repressed relative to log phase bacilli 
(drrB, drrC, emrB and Rv2459). This may be a possible explanation for 
increased efflux-based tolerance, but little is known about the specificity of each 
transporter. The expression profiles of a subset of these genes were verified by 
qRT-PCR (Figure 4); this showed excellent correlation between ratios 
generated from microarray and qRT-PCR techniques. 
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Complex transcriptional responses reflecting the changing physiological 
state of bacilli in NRP2 likely affect INH efficacy 
Unlike mutations to single genes that affect the primary target of INH or its 
modification into an active molecule that result in INH resistance, adaptations 
involving the differential expression of many genes involved in respiratory and 
metabolic pathways may influence INH tolerance in NRP2. For example, the 
maintenance of redox potential in NRP2 bacilli is very different to log phase 
aerobically respiring bacilli. This may prohibit the conversion of INH to INH-NAD 
adduct (akin to the inactivation of KatG). Cytochrome P450 genes and their 
putative redox partners (54) were differentially regulated in NRP2 relative to log 
phase; with cyp51, cyp124, cyp125, cyp130, cyp132, fdxA, fdxC, fdxD and fprB, 
fprD induced, and cyp121, cyp135A1, cyp136, cyp140, cyp141, cyp143 
repressed. Additionally, the requirement for cytochrome F420 may differ (47) with 
the NADPH-dependent glucose-6-phosphate dehydrogenases (zwf1 and zwf2) 
down-regulated, and F420-requiring glucose-6-phosphate dehydrogenases 
(encoded by fgd1 and fgd2) induced in NRP2. Mutations conferring INH 
resistance in genes coding for mycothiol biosynthesis (mshA, mshC, mshD in 
M.smegmatis) (55) and aphC (56) have also been suggested to reduce the 
capacity for pro-drug conversion, resulting in increased tolerance to INH. 
However these genes were not significantly differentially expressed in NRP2 
relative to log phase bacilli. Most interestingly, recent evidence suggests that 
M.tuberculosis is able to maintain redox potential using the anabolism of 
propionate-derived lipids as a reductant sink (57). A range of genes involved in 
fatty acid metabolism were differentially regulated in NRP2 relative to log phase 
(Supplementary Table 1). Furthermore, modulation of lipid metabolism in NRP2 
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may transform the architecture of the mycobacterial cell, which has been 
observed to thicken in stationary phase bacilli (58). Changes to the cell wall 
structure affecting cell permeability (or the suppression of porin expression) 
may impact on a range of physiological processes (59); not least in this scenario, 
limiting drug uptake that may result in increased tolerance to INH in non-
replicating bacilli. 
 
Both fabG1 (mabA) and inhA were repressed in NRP2 compared to log phase 
growth; inhA was down-regulated 2-3 fold as determined by microarray and 
qRT-PCR. This reduction in INH target (inhA) is perhaps consequent on a 
redundant metabolic role for FASII in NRP2 due to the absence of cell wall 
synthesis in the non-replicating state. As such, INH does not induce a 
compensatory response in NRP2 as cell wall biosynthesis is already 
homeostatically down-regulated. Additionally, genes involved in mycolic acid 
modification cmaA2, cmrA, mmaA2, mmaA3, mmaA4 and umaA1 were also 
repressed in NRP2 relative to log phase bacilli. DNA replication encoding genes 
dnaA, dnaB, dnaE1, dnaE2, dnaN, gyrA and ssb (60) were down-regulated as 
expected in NRP2 relative to log phase growth, as were recA, recF and recR. 
The dihydrofolate reductase (product of dfrA), an essential precursor to DNA 
replication and postulated to be a target for INH (17), was also repressed in 
NRP2. It is therefore likely that it is the reduced requirement for mycolic acids 
and the FASII cycle, necessary for de novo cell wall biosynthesis, in NRP2 as 
replication ceases that confers phenotypic tolerance to INH. 
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Use of transcriptional profiling to screen for NRP and INH-responsive 
genes that may influence M.tuberculosis drug tolerance 
Delineating the transcriptional response of M.tuberculosis to anti-microbial 
agents has lead to the characterization of mechanisms affecting drug tolerance. 
For example, the iniB/A/C genes, encoding an MDR-like pump, were identified 
to be induced after INH treatment in M.tuberculosis (61). While deletion mutants 
were more sensitive to killing by INH; over-expression conferred resistance to 
both INH and ethambutol (62). This transmembrane complex likely acts as an 
efflux pump maintaining cellular functions after the perturbation of cell wall 
biosynthesis. We reasoned that distinguishing genes that were differentially 
expressed in NRP2 that were also INH-responsive might reveal novel pathways 
that affect INH tolerance. We used the transcriptional program initiated by 
exposure to INH in log phase bacilli (in an INH-treated log phase vs. drug-free 
log phase comparison) to screen the 100s of genes differentially regulated in 
NRP2 relative to log phase bacilli (drug-free NRP2 vs. drug-free log phase) 
(Figure 5). 
 
We isolated 23 genes (Box A) that were significantly induced by INH exposure 
that were also up-regulated in drug-free NRP2 relative to untreated log phase 
bacilli. 22 genes (Box B) repressed by INH were correspondingly repressed in 
NRP2 compared to log phase bacilli (Supplementary Table 4). 7 genes involved 
in fatty acid metabolism were induced in both NRP2 and INH-treated log phase 
bacilli (fabG4, fadE5, fadA, fadB, prpC, fadE24 and fadE23) perhaps reflecting 
the redirection of lipid precursors, or metabolic shift to lipid degradation after 
environmental challenge. In addition, fadD26, ppsA and ppsD, part of the gene 
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cluster responsible for the biosynthesis of phthiocerol dimycocerosate, were 
induced in both scenarios. Over-expression of this propionate-derived complex 
lipid may modify the redox status of bacilli, and might also alter cell wall 
permeability, influencing INH tolerance. Furthermore, three genes that may also 
contribute to redox potential, fprB, an NADPH:aderenodoxin oxidoreductase 
(and the adjacent conserved hypothetical Rv0885), together with possible 
oxidoreducatase (Rv1855c), and putative monooxygenase (Rv3049c) were also 
induced. Other gene products that might influence drug kinetics such as the 
predicted membrane proteins of unknown function, Rv0446c, Rv3346c, 
Rv3355c and Rv3675 were up-regulated in NRP2 and after INH exposure. 
Interestingly, pknG, encoding a protein kinase associated with the regulation of 
M.tuberculosis metabolism (63) and the ability to survive intracellularly (64), was 
induced by both INH and NRP2. The loss of pknG function has been previously 
implicated in the increased sensitivity of M.smegmatis to multiple antibiotics (65), 
perhaps due to a decrease in cell wall hydrophobicity. In addition, quantitative 
RT-PCR (Figure 4) revealed that icl1 (encoding isocitrate lyase, part of the 
glyoxylate bypass), narX (involved in nitrate reduction), and tgs1 (a 
triacylglycerol synthase) were all NRP2 and INH-responsive. These three genes 
have all been associated with the ability of M.tuberculosis to persist in vivo (66) 
(67) (42) (68).  
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Conclusions 
Understanding why drugs do and don’t work during TB chemotherapy should 
advance novel drug design strategies, and reveal a little about the in vivo 
physiological states of M.tuberculosis bacilli that clearly influence the efficacy of 
antibiotic regimens. Transcriptional profiling is a powerful tool in this respect, 
mapping the expression pattern of all annotated genes in a whole-genome 
approach to defining the adaptations necessary for M.tb survival. This strategy 
does not however take into account processes affecting protein activity that also 
likely influence drug action. Here, we contrasted the M.tb transcriptional 
response to isoniazid in log phase and non-replicating bacilli (NRP2) as a model 
for INH tolerance. The Wayne model was selected to represent non-growing 
bacilli as this model is strictly defined, well characterized, and likely results in a 
largely homogenous M.tuberculosis population as bacilli display features of 
synchronous growth on exit from NRP2 (31). Thus, a comparison between log 
phase, with the predominant gene expression signature derived from rapidly 
multiplying bacilli, and NRP2 bacilli should model the differences between INH-
sensitive and INH-tolerant bacterial populations. Exposure of NRP2 bacilli to 
INH did not elicit a transcriptional response, and the RNA abundance of genes 
inducible by INH in log phase bacilli did not change after exposure of NRP2 
bacilli to INH. This correlates with findings by Karakousis and colleagues who 
found the INH-mediated transcriptional program greatly diminished in oxygen 
and nutrient depleted in vitro models, and in murine lung tissue after 6 weeks 
aerosol infection (34). 
 
 24 
Tolerance to INH in NRP2 bacilli cannot be correlated to the changing 
transcriptional profiles (comparing drug-free NRP2 to log phase bacilli) of genes 
directly implicated in INH resistance through resistance conferring mutations. 
However, it should be noted that factors affecting protein activity, such as the 
reduction of KatG catalase-peroxidase activity in hypoxic conditions (50), have 
not been characterized in this study. Phenotypic tolerance in NRP2 is likely the 
result of complex multi-gene adaptations to limited oxygen and diminishing 
carbon resources as bacterial multiplication slows and stops. The reduced 
requirement for mycolic acids and the FASII cycle in non-replicating bacilli 
renders bacilli tolerant to the effects of INH. Other factors such as redox state 
and cell wall permeability may also contribute to the abrogation of killing by INH 
in non-growing M.tuberculosis bacilli. 
 
We speculate that the induction of a subset of genes involved in lipid 
metabolism and capable of performing oxidative functions in both NRP2 and 
after exposure to INH suggest that specific pathways remodelling the metabolic 
and respiratory state of M.tuberculosis may also influence the efficacy of INH 
killing. Furthermore, many of these genes have been identified to be up-
regulated after macrophage infection (69) (70). Could the induction of these 
pathways in replicating intracellular bacilli account for the significant decrease in 
INH sterilizing ability between axenic culture and after macrophage infection (71), 
or in vivo (72)? Finally, the up-regulation of tgs1, involved in triacylglycerol lipid 
body formation, after INH exposure and in NRP2 bacilli suggests that the 
metabolic consequences of specific growth constraints that induce a drug-
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tolerant fat and lazy mycobacterial phenotype are also encountered in the 
human lung (42). 
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Executive summary 
1. Effective TB chemotherapy is hampered by prolonged treatment necessary to 
remove persistent bacilli, most likely because most front-line antibiotics primarily 
kill replicating bacilli. 
 
2. An understanding of how and why M.tuberculosis bacilli become 
phenotypically tolerant to some antibiotics would illuminate current drug design 
programs, aimed at reducing duration of treatment from months to weeks. 
 
3. Transcriptional profiling may be used to reveal important metabolic and 
physiological adaptations associated with M.tuberculosis infection in vivo and 
underpinning phenotypic tolerance to antibiotics. This genome-wide approach is 
also valuable in highlighting genes of interest that have no predicted function 
which may not have been identified by gene-specific assays. Novel insights into 
underlying mechanisms may thus be discovered. 
 
4. M.tuberculosis bacilli in non-replicating persistence state 2 (NRP2) do not 
respond transcriptionally to INH exposure, and are tolerant to INH. Tolerance to 
INH in non-growing bacilli is therefore not a result of INH-inducible adaptive 
responses, but rather a reflection of the underlying metabolic state in which INH 
has minimal effect. 
 
5. Altered transcript abundance of key genes implicated in INH resistance 
(involved in drug activation or target manipulation) do not explain why NRP2 
bacilli become tolerant to INH. 
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6. The reduced requirements for mycolic acids and disparate redox state of 
non-growing bacilli probably result in tolerance to the effects of INH exposure. 
 
7. Genes involved in lipid metabolism and alternative redox pathways may play 
functionally significant roles in INH-tolerant M.tuberculosis bacilli that persist 
through chemotherapy. 
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Future perspective 
There are several technological advances that impact on understanding drug 
resistance mechanisms, which together may resolve the important phenomenon 
of tolerance in M.tuberculosis. 
 
1. The application of high-throughput whole genome DNA sequencing will 
transform M.tuberculosis resistance testing by mapping mutations to drug mode 
of action. Currently, in the absence of comprehensive, genome-wide correlation 
of genotypic changes with phenotypic drug resistance, it is difficult to predict 
resistance simply by sequence analysis for single nucleotide polymorphisms 
(SNPs). Implementation of, the soon to be available, rapid and cost effective 
third generation highly parallel sequencing platforms will permit every 
M.tuberculosis isolate to be sequenced. The correlation of genomic sequence to 
phenotypic resistance profile of many thousands of isolates will result in 
complex predictive modeling of resistance-modifying SNPs. However, it would 
be unwise to abandon sensitivity testing completely. This SNP mapping 
together with consequent gene-specific studies will expose multiple primary and 
secondary drug targets further elucidating mechanisms of antibiotic killing. It 
may also reveal new classes of mutation conferring low-level resistance, 
affecting features such as cell permeability or growth rate. Furthermore, such 
genome-wide analyses will begin to uncover linkage between resistance 
mutations, as well as a large number of mutations that have no effect on 
antibiotic resistance at all. The resulting payoff will provide clinicians with a 
resistance profile for problem isolates, enabling chemotherapy to be tailored 
effectively. Although tolerance is an adaptive process, genotypic changes 
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revealed by sequencing will define a panel of genes and highlight complex 
pathways that when modified at the mRNA or protein level may also influence 
antibiotic tolerance. 
 
2. Predictive modeling of drug tolerance using transcriptional profiling and 
systems approaches to test M.tuberculosis drug-tolerant phenotypes will be 
instrumental in defining in vitro conditions that reflect the complex in vivo status. 
This will enable tolerance mechanisms to be investigated in models that 
accurately represent the antibiotic sensitivity profile of bacilli during natural 
infection, and allow drug-screening programs to target persistent-like bacilli. 
Modeling the changing physiological state of bacilli exposed to different in vivo 
or intracellular environments, diverse carbon sources and varied oxidative 
scenarios (defining mRNA, protein or metabolite levels) will help to delineate the 
unique transcriptional profiles derived from human sputa or lung tissue sections. 
 
3. Single cell technologies and microfluidics have enabled bacterial populations 
to be visualized and differentiated; further advances in these fields will allow 
responses of individual bacteria to the changing microenvironment to be 
assayed. The identification and characterization of sub-populations of 
phenotypically diverse bacteria and the factors that influence their creation 
promises to reveal much about persisters, and their potential roles during 
infection. This, together with transcriptionally-defined drug-screening targeted to 
specific bacterial metabolic and respiratory states, should pave the way for 
discovery of novel compounds that kill non-replicating persistent bacteria. The 
continued support and patience of funding agencies will be required to smelt 
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these silver bullets with the hope of eliminating the hidden monster of persistent 
infection. 
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Figure legends 
Figure 1a 
The transcriptional programs induced by isoniazid exposure in log phase, NRP1 
and NRP2 growth states. The expression pattern of 71 genes induced by INH 
treatment in aerobic conditions are clustered alongside the transcriptional 
activity of these genes after INH exposure in NRP1 and NRP2. The genes are 
displayed as rows, growth conditions as columns. Asterisked genes were also 
INH-responsive in NRP1. No genes were significantly differentially expressed in 
NRP2 after INH treatment. Red coloring signifies induction; blue denotes 
repression relative to the respective drug-free growth state controls. 
 
Figure 1b 
The diminished transcriptional response to INH exposure in NRP2. The gene 
expression profiles of 100 genes (71 induced, 29 repressed) significantly 
differentially expressed after INH treatment in aerobic conditions are plotted (-/+ 
INH) alongside the expression pattern of these genes in NRP1 and NRP2. The 
expression ratios are presented as fold change relative to drug-free growth 
state controls. 
 
Figure 2 
The absence of a transcriptional response to INH in NRP2 bacilli, verified by 
quantitative RT-PCR with a panel of genes chosen to exemplify the INH 
transcriptional signature and the physiological status of bacilli. Expression 
ratios, marked in fold change, were calculated relative to sigA and drug-free 
growth controls using the ΔΔCt method. Standard deviations from triplicate 
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samples are marked. Red-pink coloring highlights genes selected to assay INH 
mechanism of action; blue coloring indicates genes chosen to illustrate the 
metabolic and respiratory state of bacilli. 
 
Figure 3 
The changes in RNA abundance of genes associated with INH resistance in log 
phase and NRP2 bacilli +/- INH relative to drug-free log phase bacilli. 
Expression ratios, derived from the microarray dataset, are plotted in fold 
change for log phase aerobic (AG) and NRP2 +/- INH treatment. Genes ordered 
by chromosome position, with gray bars highlighting adjacent genes. 
Annotations in black indicate that the over-expression of these gene products in 
NRP2 may be hypothesized to increase INH tolerance. Conversely, the 
repression of genes (marked in grey) might be expected to increase INH 
tolerance in NRP2. 
 
Figure 4 
Quantitative RT-PCR confirming the differential regulation of INH-responsive 
genes and genes indicative of bacterial metabolic state in log phase (AG) and 
NRP2 relative to drug-free log phase bacilli. Expression ratios +/- INH, 
measured in fold change, were calculated relative to sigA and untreated log 
phase control using the ΔΔCt method. Standard deviations from triplicate 
samples are marked. 
 
 42 
Figure 5 
The expression pattern of INH-responsive genes in log phase and NRP2 bacilli 
+/- INH relative to drug-free log phase bacilli. 100 genes, identified as 
significantly differentially regulated after INH exposure in aerobic conditions, 
were clustered alongside the NRP2 transcriptional profiles. Boxes A and B 
highlight genes either induced or repressed after both INH exposure and 
transition to NRP2 compared to untreated log phase bacilli. The genes are 
displayed as rows, growth conditions +/- INH as columns. Red coloring signifies 
induction; blue denotes repression relative to log phase drug-free control. 
Asterisked genes were significantly differentially expressed in both drug-free 
NRP2 and INH-treated aerobic bacilli compared to untreated log phase bacilli. 
 
Supplementary Table S1 
Genes significantly differentially regulated in NRP2 compared to log phase 
bacilli, ttest p<0.05, Benjamini and Hochberg multiple testing correction, >1.5 
fold change. Ordered by chromosome position. 
 
Supplementary Table S2 
Genes significantly differentially expressed after isoniazid treatment of log 
phase bacilli relative to drug-free control, p<0.05, Benjamini and Hochberg 
multiple testing correction, >1.5 fold change. Ordered by chromosome position. 
 
Supplementary Table S3 
Primers and probe sequences (5’-3’) for the panel of qRT-PCR assays used in 
this study. 
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Supplementary Table S4 
Figure 5 Boxes A and B. Genes identified to be both INH-responsive and 
differentially regulated in NRP2 relative to log phase bacilli. Ordered by 
chromosome position. 
 
Supplementary Figure S1 
Growth of M.tuberculosis in aerobic conditions (plotted in red), and in non-
replicating persistence stage 1 (NRP1, green) and NRP2 (blue). Vertical arrows 
indicate isoniazid exposure and RNA extraction time intervals at day 3 
(aerobic), day 6 (NRP1) and day 21 (NRP2). The standard deviations between 
replicate experiments are marked as error bars. 
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